10-Q: Alkermes Reports Q3 2024 Results: Product Sales Rise, Royalty Revenue Declines Post-Arbitration

Alkermes plc reported increased product sales but a decrease in manufacturing and royalty revenues for the third quarter of 2024, following the conclusion of a key arbitration and the expiration of a royalty agreement.

Summary

• Alkermes reported a net income from continuing operations of $92.8 million, or $0.57 per share basic, for the three months ended September 30, 2024, compared to $91.6 million, or $0.55 per share basic, for the same period in 2023.
• Product sales, net, increased to $273 million in Q3 2024 from $231.8 million in Q3 2023, driven by growth in VIVITROL, ARISTADA, and LYBALVI.
• Manufacturing and royalty revenues decreased to $105.1 million in Q3 2024 from $149.1 million in Q3 2023, primarily due to the expiration of a royalty on INVEGA SUSTENNA sales and the prior year's recognition of back royalties.
• Operating expenses decreased by $18.4 million in Q3 2024 compared to Q3 2023, contributing to the increase in net income.
• For the nine months ended September 30, 2024, net income from continuing operations was $226.4 million, or $1.36 per share basic, compared to $358.6 million, or $2.16 per share basic, for the same period in 2023.
• The decrease in net income for the nine-month period was primarily due to a $256.1 million decrease in manufacturing and royalty revenue and a $42.9 million increase in the income tax provision.
• The company repurchased approximately 4.4 million ordinary shares for $115.3 million during the quarter, with $200 million remaining authorized under the share repurchase program.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to increased product sales and decreased operating expenses, but tempered by the significant decrease in royalty revenue and the overall decrease in net income for the nine-month period. The company's strong cash position and share repurchase program are positive indicators, but the risks related to patent expirations and legal proceedings are concerning.

Positives

• Product sales, net, increased across all proprietary products, with LYBALVI showing the strongest growth.
• Operating expenses decreased, contributing to improved profitability.
• The company has a strong cash position with $396.3 million in cash and cash equivalents.
• The company continues to invest in its pipeline, particularly in the ALKS 2680 program.
• The company is actively repurchasing shares, indicating confidence in its future prospects.

Negatives

• Manufacturing and royalty revenues decreased significantly due to the expiration of the INVEGA SUSTENNA royalty and the prior year's recognition of back royalties.
• Net income from continuing operations decreased for the nine-month period compared to the previous year.
• The company faces potential competition from generic versions of its licensed products, which could impact future revenues.
• The company is involved in ongoing legal proceedings, which could result in financial liabilities.

Risks

• The expiration of the INVEGA SUSTENNA royalty will negatively impact future royalty revenues.
• The company faces potential competition from generic versions of its licensed products, which could impact future revenues.
• Ongoing legal proceedings could result in financial liabilities.
• The company's R&D programs are subject to risks and uncertainties, and may not result in successful new products.
• The company is exposed to currency exchange rate fluctuations.

Future Outlook

The company expects royalty revenues from net sales of the long-acting INVEGA products to decrease in the near-term, as the royalty revenues related to net sales of INVEGA SUSTENNA ended on August 20, 2024. The company expects that its existing cash, cash equivalents and investments will be sufficient to finance its anticipated working capital and other cash requirements for at least the 12 months following the date from which its financial statements were issued.

Management Comments

• Management believes that the company's existing cash, cash equivalents and investments will be sufficient to finance its anticipated working capital and other cash requirements for at least the next 12 months.
• Management is focused on advancing its R&D programs, particularly ALKS 2680.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition from both branded and generic products. Alkermes' focus on neuroscience and its proprietary technologies positions it to address unmet medical needs, but it also faces risks related to patent expirations and generic competition. The company's collaboration agreements and licensing arrangements are common in the industry, allowing for shared development costs and market access.

Comparison to Industry Standards

• Alkermes' revenue mix, with a combination of proprietary product sales and royalty revenues, is typical of a mid-sized biopharmaceutical company.
• The company's R&D spending, while significant, is in line with industry averages for companies developing novel therapeutics.
• The company's share repurchase program is a common strategy for returning value to shareholders, particularly when a company has a strong cash position.
• The decrease in royalty revenue due to patent expiration is a common challenge in the pharmaceutical industry, highlighting the importance of a robust pipeline.
• The company's legal proceedings are not uncommon in the industry, as companies often face patent challenges and product liability claims.

Legal Proceedings

• The company is involved in a patent infringement lawsuit related to VUMERITY.
• The company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL.
• The company is involved in a product liability case alleging that the FDA-approved VIVITROL labeling was inadequate.
• The company is involved in litigation with Acorda Therapeutics, Inc.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and the potential for future revenue declines due to patent expirations.
• Employees may be impacted by the company's cost-cutting measures, including headcount reductions.
• Customers may benefit from the company's continued development of new and innovative treatments.
• Suppliers may be impacted by changes in the company's manufacturing and supply chain.

Next Steps

• The company expects to initiate Vibrance-3, a phase 2 study in patients with idiopathic hypersomnia in 2025.
• The company will continue to monitor and manage its investment portfolio.
• The company will continue to evaluate its products under development based on performance in clinical trials and commercial viability.

Key Dates

Keywords

Alkermes, pharmaceuticals, neuroscience, VIVITROL, ARISTADA, LYBALVI, INVEGA, VUMERITY, ALKS 2680, product sales, royalty revenue, share repurchase, financial results, quarterly report